For two hundred years vaccines have been administered by intramuscular injection.  Vaxart’s oral vaccine pills may change everything.

Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body:  the mucosal areas, including the mouth, the nose and the gut.  They are designed to  trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders.

Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.


Our mission is to make the world a better and safer place by developing transformative vaccines against common viral infections that hold out the promise of providing stronger, broader and more durable protection and, because they come in the form of a small pill, being quicker and less expensive to distribute.


Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.

Its development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication.

Join the Movement.

Subscribe to our newsletter.